Should the emergence of new agents change the management of patients with acute coronary syndromes without ST-segment elevation?

被引:3
作者
Califf, RM
Holmes, DR
机构
[1] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC 27715 USA
[2] Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA
关键词
D O I
10.1053/hj.1999.v138.a102300
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cardiac catheterization for diagnostic angiography and revascularization, if indicated, plays an increasing role in the management of acute coronary syndromes in the absence of ST elevation. The disagreement between those who favor a conservative approach to intervention and those who favor an aggressive approach centers on whether interventions should be routinely performed in all patients, New pharmacotherapies have emerged that reduce the incidence of death and myocardial infarction in this group of patients. At the same time, the success rate of percutaneous revascularizations has been improved by the widespread use of stenting, and a reduction in complications has been achieved with new pharmacologic agents. As therapies are rapidly evolving, it is difficult to extrapolate the results of earlier clinical trials to the most current practices. Until evidence is available comparing optimal medical management with the most successful interventional techniques, the best approach to intervention is likely to remain the subject of discussion.
引用
收藏
页码:S586 / S594
页数:9
相关论文
共 29 条
[1]  
*AM HEART ASS, 1997, HEART STROK STAT UPD
[2]  
Bazzino O, 1998, NEW ENGL J MED, V338, P1498
[3]  
Bazzino O, 1998, NEW ENGL J MED, V338, P1488
[4]   Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy [J].
Boden, WE ;
O'Rourke, RA ;
Crawford, MH ;
Blaustein, AS ;
Deedwania, PC ;
Zoble, RG ;
Wexler, LF ;
Kleiger, RE ;
Pepine, CJ ;
Ferry, DR ;
Chow, BK ;
Lavori, PW .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (25) :1785-1792
[5]  
BRAUNWALD E, 1994, CIRCULATION, V89, P1545
[6]   USE OF A MONOCLONAL-ANTIBODY DIRECTED AGAINST THE PLATELET GLYCOPROTEIN IIB/IIIA RECEPTOR IN HIGH-RISK CORONARY ANGIOPLASTY [J].
CALIFF, RM ;
SHADOFF, N ;
VALETT, N ;
BATES, E ;
GALEANA, A ;
KNOPF, W ;
SHAFTEL, J ;
BENDER, MJ ;
AVERSANO, T ;
RAQUENO, J ;
GURBEL, P ;
COWFER, J ;
COHEN, M ;
CROSS, P ;
BITTL, J ;
EDDINGS, K ;
TAYLOR, M ;
DEROSA, K ;
HATTEL, L ;
COOPER, L ;
ESHELMAN, B ;
FINTEL, D ;
NIEMYSKI, P ;
KLEIN, L ;
KENNEDY, H ;
THORNTON, T ;
KEREIAKES, D ;
MARTIN, L ;
ANDERSON, L ;
HIGBY, N ;
ELLIS, S ;
BREZINA, K ;
GEORGE, B ;
CHAPEKIS, A ;
SMITH, D ;
ANWAR, A ;
GERBER, TL ;
PRITCHARD, GL ;
MYLER, R ;
SHAW, R ;
MURPHY, M ;
WARD, K ;
MADIGAN, NP ;
BLANKENSHIP, J ;
HALBERT, M ;
FLANAGAN, C ;
TANNENBAUM, M ;
POLICH, M ;
STEVENSON, C ;
TCHENG, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (14) :956-961
[7]   A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease [J].
Cohen, M ;
Demers, C ;
Gurfinkel, EP ;
Turpie, AGG ;
Fromell, GJ ;
Goodman, S ;
Langer, A ;
Califf, RM ;
Fox, KAA ;
Premmereur, J ;
Bigonzi, F .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (07) :447-452
[9]   LOW-MOLECULAR-WEIGHT HEPARIN IN PREVENTION OF RESTENOSIS AFTER ANGIOPLASTY - RESULTS OF ENOXAPARIN RESTENOSIS (ERA) TRIAL [J].
FAXON, DP ;
SPIRO, TE ;
MINOR, S ;
COTE, G ;
DOUGLAS, J ;
GOTTLIEB, R ;
CALIFF, R ;
DOROSTI, K ;
TOPOL, E ;
GORDON, JB ;
OHMEN, M ;
RAIZNER, A ;
PAR, T ;
CURRIER, J ;
HANKIN, B .
CIRCULATION, 1994, 90 (02) :908-914
[10]   A RANDOMIZED COMPARISON OF CORONARY-STENT PLACEMENT AND BALLOON ANGIOPLASTY IN THE TREATMENT OF CORONARY-ARTERY DISEASE [J].
FISCHMAN, DL ;
LEON, MB ;
BAIM, DS ;
SCHATZ, RA ;
SAVAGE, MP ;
PENN, I ;
DETRE, K ;
VELTRI, L ;
RICCI, D ;
NOBUYOSHI, M ;
CLEMAN, M ;
HEUSER, R ;
ALMOND, D ;
TEIRSTEIN, PS ;
FISH, RD ;
COLOMBO, A ;
BRINKER, J ;
MOSES, J ;
SHAKNOVICH, A ;
HIRSHFELD, J ;
BAILEY, S ;
ELLIS, S ;
RAKE, R ;
GOLDBERG, S .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (08) :496-501